Gestational trophoblastic neoplasia (including hydatidiform mole)

A 34-year-old woman had a suction evacuation for a complete hydatidiform mole six weeks ago. She has been well, using reliable contraception, but her serial hCG values have plateaued — 820, 845, 810 and 830 IU/L across four weekly tests. This is post-molar GTN by the FIGO hCG-plateau criterion. Your job is to confirm the hCG is real, stage and score her with the FIGO 2000 system, register her with the regional trophoblast centre, and start single-agent chemotherapy for what is almost certainly low-risk disease that will be cured with fertility preserved.^[1][5]

Overview and definition

Gestational trophoblastic disease (GTD) is a spectrum of interrelated disorders originating from the placenta. Its premalignant forms are the complete and partial hydatidiform moles; its malignant forms — invasive mole, choriocarcinoma, and the rare placental-site and epithelioid trophoblastic tumours — are termed gestational trophoblastic tumours or gestational trophoblastic neoplasia (GTN).^[14]

What makes GTN unusual among cancers is that it is always driven by trophoblast, so human chorionic gonadotropin (hCG) is both the tumour marker that tracks every form of the disease and the hormone that drives its complications. It is exquisitely chemosensitive, produces hCG proportionate to tumour burden, and metastasises haematogenously to the lungs (commonest), vagina, brain and liver. Centralised registration and risk-stratified treatment are reasons overall cure rate now exceeds 95% with fertility retained.^[5][14]

References19ShowHide

1. [1]FIGO Oncology Committee FIGO staging for gestational trophoblastic neoplasia 2000. FIGO Oncology Committee. Int J Gynaecol Obstet, 2002.PMID 12065144
2. [2]Ngan HY, Bender H, Benedet JL, et al. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet, 2003.PMID 14763174
3. [3]Kohorn EI The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: description and critical assessment. Int J Gynecol Cancer, 2001.PMID 11285037
4. [4]Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, Braga A, Garrett A Diagnosis and management of gestational trophoblastic disease: 2025 update. Int J Gynaecol Obstet, 2025.PMID 40631439
5. [5]Soper JT Gestational Trophoblastic Disease: Current Evaluation and Management. Obstet Gynecol, 2021.PMID 33416290
6. [6]McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, Newlands ES Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol, 2002.PMID 11919242
7. [7]Osborne RJ, Filiaci V, Schink JC, Mannel RS, Alvarez Secord A, Kelley JL, et al. Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk postmolar gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol, 2011.PMID 21263100
8. [8]Jiang F, Guan CL, Jiao LZ, Xu T, Wan XR, Shi SS, et al. Efficacy and safety of biweekly single-dose actinomycin D versus multiday methotrexate in low-risk gestational trophoblastic neoplasia: a prospective multicenter randomized trial. Ann Oncol, 2025.PMID 40543844
9. [9]Alifrangis C, Agarwal R, Short D, Fisher RA, Sebire NJ, Harvey R, Savage PM, Seckl MJ EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol, 2013.PMID 23233709
10. [10]Bower M, Newlands ES, Holden L, Short D, Brock C, Rustin GJS, Bagshawe KD EMA/CO for high-risk gestational trophlastic tumors: results from a cohort of 272 patients. J Clin Oncol, 1997.PMID 9215835
11. [11]Lurain JR Advances in management of high-risk gestational trophoblastic tumors. J Reprod Med, 2002.PMID 12092013
12. [12]Feltmate CM, Genest DR, Wise L, Bernstein MR, Goldstein DP, Berkowitz RS Placental site trophoblastic tumor: a 17-year experience at the New England Trophoblastic Disease Center. Gynecol Oncol, 2001.PMID 11520134
13. [13]Berkowitz RS, Goldstein DP Clinical practice. Molar pregnancy. N Engl J Med, 2009.PMID 19369669
14. [14]Seckl MJ, Sebire NJ, Berkowitz RS Gestational trophoblastic disease. Lancet, 2010.PMID 20673583
15. [15]Castrillon DH, Sun D, Weremowicz S, Fisher RA, Crum CP, Genest DR Discrimination of complete hydatidiform mole from its mimics by immunohistochemistry of the paternally imprinted gene product p57KIP2. Am J Surg Pathol, 2001.PMID 11688455
16. [16]Lybol C, Sweep FC, Ottevanger PB, Massuger LF, Thomas CM Linear regression of postevacuation serum human chorionic gonadotropin concentrations predicts postmolar gestational trophoblastic neoplasia. Int J Gynecol Cancer, 2013.PMID 23714707
17. [17]Albright BB, Shorter JM, Mastroyannis SA, Ko EM, Schreiber CA, Sonalkar S Gestational Trophoblastic Neoplasia After Human Chorionic Gonadotropin Normalization Following Molar Pregnancy: A Systematic Review and Meta-analysis. Obstet Gynecol, 2020.PMID 31809433
18. [18]Elias KM, Berkowitz RS, Horowitz NS Surgical Management of Gestational Trophoblastic Neoplasia. Hematol Oncol Clin North Am, 2024.PMID 39244451
19. [19]Ngan HYS, Seckl MJ, Horowitz N, Cheung ANY, Braga A, Sekharan PK, Fridsten S, Garrett A, Yanaihara N, Wilailak S, Schmalfeldt B FIGO staging for gestational trophoblastic neoplasia: 2026 Int J Gynaecol Obstet, 2026.PMID 42473063